XML 60 R43.htm IDEA: XBRL DOCUMENT v3.3.1.900
Available-for-Sale Securities and Fair Value Measurements (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Available-for-sale securities      
Amortized Cost $ 176,778 $ 285,483  
Gross Unrealized Gains 0 35  
Gross Unrealized Losses (2) (122)  
Other Than Temporary Impairment Loss 0 (3,752) $ 0
Estimated Fair Value $ 176,776 281,644  
Maturity period for marketable securities      
Maximum contractual maturity period 1 year    
Average duration 1 month    
Proceeds from sale of available-for-sale securities $ 108,077 7,211 $ 22,600
Theravance Biopharma      
Maturity period for marketable securities      
Gain on sales of the securities 1,200    
Issuer of available-for-securities other than Theravance Biopharma      
Maturity period for marketable securities      
Proceeds from sale of available-for-sale securities 100,400    
Cash and cash equivalents      
Available-for-sale securities      
Estimated Fair Value 148,673 95,090  
Short-term investments      
Available-for-sale securities      
Estimated Fair Value 28,103 143,698  
Marketable securities      
Available-for-sale securities      
Estimated Fair Value 0 42,856  
U.S. government securities      
Available-for-sale securities      
Amortized Cost   30,019  
Gross Unrealized Gains   24  
Gross Unrealized Losses   0  
Other Than Temporary Impairment Loss   0  
Estimated Fair Value   30,043  
U.S. government agency securities      
Available-for-sale securities      
Amortized Cost 14,406 34,756  
Gross Unrealized Gains 0 6  
Gross Unrealized Losses (1) (12)  
Other Than Temporary Impairment Loss 0 0  
Estimated Fair Value 14,405 34,750  
Corporate notes      
Available-for-sale securities      
Amortized Cost 2,702 80,880  
Gross Unrealized Gains 0 5  
Gross Unrealized Losses (1) (110)  
Other Than Temporary Impairment Loss 0 0  
Estimated Fair Value 2,701 80,775  
Commercial paper      
Available-for-sale securities      
Amortized Cost 10,997 34,469  
Gross Unrealized Gains 0 0  
Gross Unrealized Losses 0 0  
Other Than Temporary Impairment Loss 0 0  
Estimated Fair Value 10,997 34,469  
Equity securities | Theravance Biopharma      
Available-for-sale securities      
Amortized Cost   10,269  
Gross Unrealized Gains   0  
Gross Unrealized Losses   0  
Other Than Temporary Impairment Loss   (3,752)  
Estimated Fair Value   6,517  
Money market funds      
Available-for-sale securities      
Amortized Cost 148,673 95,090  
Gross Unrealized Gains 0 0  
Gross Unrealized Losses 0 0  
Other Than Temporary Impairment Loss 0 0  
Estimated Fair Value $ 148,673 $ 95,090